Christopher A. Eide - Concepedia

Author

Christopher A. Eide

Oregon Health & Science University ORCID

Also Known As

C A Eide, C Eide, Christopher A Eide, Christopher A. Eide, Christopher Eide, Christopher A. Eide

372

Publications

10.1K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University Howard Hughes Medical Institute University of Utah Huntsman Cancer Institute University of Colorado Denver

About

Christopher A. Eide is an author at Oregon Health & Science University specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	4.3K
2	Cell Biology	12	13	2.5K
3	Engineering	1	1	103
4	Health Sciences	1	1	16
5	Cellular Physiology	1	1	29

Christopher A. Eide

Publications

Citations

H-Index

Page 1

	Year	Citations
Functional genomic landscape of acute myeloid leukaemia Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly, Nature Hematological MalignancyChromatinFunctional GenomicsMixed-phenotype Acute LeukemiaGenetics	2018	1.4K
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu, Cancer Cell Hematological MalignancyTumor BiologyChronic Myeloid LeukemiaOncologyPan-bcr-abl Inhibitor	2009	1.2K
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Thomas O’Hare, Christopher A. Eide, Michael W. Deininger Blood	2007	637
Oncogenic<i>CSF3R</i>Mutations in Chronic Neutrophilic Leukemia and Atypical CML Julia E. Maxson, Jason Gotlib, Daniel A. Pollyea, New England Journal of Medicine	2013	562
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations Heather A. Bradeen, Christopher A. Eide, Thomas O’Hare, Blood	2006	397
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Cancer Cell Hematological MalignancyPh Chromosome-positive LeukemiaGeneticsMolecular GeneticsCancer Genetics	2014	363
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia Daniel Bottomly, Nicola Long, Anna Reister Schultz, Cancer Cell	2022	336
Activating alleles of JAK3 in acute megakaryoblastic leukemia Denise K. Walters, Thomas Mercher, Ting-Lei Gu, Cancer Cell Hematological MalignancyMixed-phenotype Acute LeukemiaGeneticsAcute Megakaryoblastic LeukemiaHematology	2006	313
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia Alyssa Carey, David K. Edwards, Christopher A. Eide, Cell Reports	2017	257
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage, Cancer Cell Allosteric Inhibitor AsciminibMedicineImmunologyPharmacotherapyPonatinib Suppresses Emergence	2019	239

Page 1